Publication | Closed Access
Single agent oral topotecan (OT) as first-line treatment for patients (pts) with extensive disease (ED) small cell lung cancer (SCLC) ineligible for standard therapy: A phase II study
33
Citations
0
References
2000
Year
OncologySingle AgentMetronomic TherapyPathologyExtensive DiseaseCancer TreatmentMedicineRadiation OncologyLung CancerStandard Therapy
No additional data available for this publication yet. Check back later!